LUND, Sweden, Dec. 17, 2019 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX), today announced that the
first patient has been successfully dosed in the Phase I study with
the wholly owned 4-1BB antibody ATOR-1017, which is being developed
for the treatment of metastasized cancer.
The Phase I study is a dose escalation study in patients with
advanced cancer and this is the first time ATOR-1017 is being
evaluated in humans. The study will be conducted at three different
clinics in Sweden and include up
to 50 patients. The primary objective of the study is to assess the
safety and tolerability of ATOR-1017 and to determine the
recommended dose for the subsequent Phase II studies.
ATOR-1017 activates 4-1BB receptors which increases the ability
of the immune system to detect and kill tumor cells. This makes
4-1BB a particularly attractive target for cancer immunotherapy.
ATOR-1017 has a unique profile related to the fact that its
immune-stimulatory function is stronger in areas where immune cells
are abundant, notably in tumors. This creates an opportunity for a
strong immune activation that can increase efficacy and reduce side
effects for the patient.
"In the preclinical studies, ATOR-1017 has showed a strong and
long-lasting immune response, and even created immunity to cancer,
while minimizing the side effects through tumor-directed immune
activation. This profile puts ATOR-1017 at the forefront of the
field and it will be very exciting to follow the continued clinical
development ", said Per Norlén, CEO of Alligator Bioscience.
For further information, please contact:
Cecilia Hofvander, Director Investor
Relations & Communications
Phone +46-46-540-82-06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the
agency of the contact persons set out above, at 1:00 p.m. CET
on December 17, 2019.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's growing pipeline includes six lead clinical and
preclinical drug candidates: mitazalimab (ADC-1013), ATOR-1015,
ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics
Inc.), ATOR-1144 and AC101 (in clinical development by Shanghai
Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq
Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55
employees. For more information, please visit
www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-first-patient-dosed-with-ator-1017-developed-for-metastasized-cancer,c2992989
The following files are available for download:
https://mb.cision.com/Main/12681/2992989/1163246.pdf
|
First patient dosed
with ATOR-1017 developed for metastasized cancer
|